California State Teachers Retirement System Purchases 10,644 Shares of Protagonist Therapeutics, Inc. $PTGX

California State Teachers Retirement System increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 22.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,677 shares of the company’s stock after buying an additional 10,644 shares during the period. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth $6,185,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada boosted its position in shares of Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after acquiring an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Protagonist Therapeutics by 0.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC raised its holdings in Protagonist Therapeutics by 283.6% during the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after purchasing an additional 99,269 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at about $987,000. Finally, Guggenheim Capital LLC boosted its stake in Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after acquiring an additional 303 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bryan Giraudo sold 6,000 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the completion of the sale, the director owned 31,825 shares in the company, valued at approximately $3,182,500. The trade was a 15.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 113,130 shares of company stock worth $11,549,340. Insiders own 5.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Truist Financial lifted their price target on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Citizens Jmp raised their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Wedbush upped their price target on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $123.00.

Protagonist Therapeutics Stock Up 1.1%

Shares of PTGX stock opened at $137.32 on Thursday. The stock has a market cap of $8.83 billion, a P/E ratio of -75.87 and a beta of 1.78. Protagonist Therapeutics, Inc. has a 52 week low of $50.49 and a 52 week high of $143.29. The company’s fifty day simple moving average is $122.46 and its two-hundred day simple moving average is $104.48.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.05. The company had revenue of $213.47 million for the quarter, compared to analysts’ expectations of $199.81 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The business’s quarterly revenue was up 3746.8% compared to the same quarter last year. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.